Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 20, 2001

View Archived Issues

Available for licensing from NIH: T-cell epitopes from NY-ESO-1 cancer antigen

MAGE-12 T-cell epitope available for licensing from NIH

Important developments at Pharmacia during 2000

PhotoCure reports highlights from 2000 and goals for 2001

KS Biomedix and Aurelium BioPharma enter proteomics alliance

Novartis receives FDA approval for Foradil Aerolizer for asthma maintenance therapy

OraPharma's Arestin cleared for U.S. launch

Distribution agreement for Pacis BCG terminated by UroCor and BioChem Pharma

Cubist reports results for fourth quarter and full year

Antiangiogenic/antitumor compound TSRI-265 specifically disrupts MMP-2 binding to alphavbeta3

V-echinocandin has significant, dose-dependent efficacy against fluconazole-resistant OPEC

First report of in vivo efficacy of HNP-1 in experimental tuberculosis

Organometallic complexes with antiestrogenic and antiproliferative effects

Prescient NeuroPharma created following merger

Acute hemodynamic effects and safety of tezosentan in NYHA class III-IV CHF

Altace approved in Canada for expanded indication

Virulizin granted orphan drug status by FDA

Pilot trial of docosanol for AIDS-associated Kaposi's sarcoma

Protopic for severe atopic dermatitis launched in U.S.

Serono initiates trial of Serostim for HARS

Cancidas introduced following late January approval by FDA

U.S. and Israeli team prepares short peptides modulating serine/threonine kinase activity

New tuftsin analogues more potent than the parent compound and orally active

Aventis describes improved salt of known vitronectin antagonist useful in osteoporosis

Inhibitors of ileal bile acid transporter and use in hypercholesterolemia

Sankyo presents new cytokine production inhibitors in recent patent

Glutamate receptor antagonist prodrug with improved oral bioavailability in animals

Novel fused imidazoles for diabetes and complications thereof

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...